Drug
Fezolinetant clinical trials
Also written ESN364 and VEOZAH™.
Keep track of what changes. Save the fezolinetant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 6
Astellas Pharma Global Development, Inc. (12) · Astellas Pharma Inc (5) · Astellas Pharma China, Inc. (3) · Ogeda S.A. (1) · Rebecca Thurston (1) · Chinese University of Hong Kong (1) · University of Colorado, Denver (1) · Yale University (1)
Often tested with
Tested in the same studies.
Enzalutamide (1) · Apalutamide (1) · Bicalutamide (1) · Hormone Therapy (1)
Studies
Open first, then newest update. How each study uses fezolinetant is read from its arms, and is right about nine times in ten.
Testing it · 27
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07783282Written as fezolinetant
- A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)RecruitingPhase 2Chinese University of Hong KongNCT07568236Written as Fezolinetant
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopauseNot yet recruitingPhase 3Astellas Pharma IncNCT07829653Written as Fezolinetant
- Fezolinetant and Vascular Health and Brain HealthNot yet recruitingPhase 3Rebecca ThurstonNCT07606664Written as Fezolinetant
- Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthRecruitingPhase 2/3University of Colorado, DenverNCT06975111Written as Fezolinetant
- FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyRecruitingPhase 2Yale UniversityNCT06917313Written as Fezolinetant
- Fezolinetant for Treating Hot Flashes in Men With Prostate CancerRecruitingPhase 2University of VermontNCT06972875Written as Fezolinetant
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyActive, not recruitingPhase 3Astellas Pharma Global Development, Inc.NCT06440967Written as Fezolinetant
- Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT TrialTerminatedPhase 2University of Michigan Rogel Cancer CenterNCT06617455Written as Fezolinetant
- A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through MenopauseCompletedPhase 3Astellas Pharma IncNCT06206421Written as Fezolinetant
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through MenopauseCompletedPhase 2Astellas Pharma Global Development, Inc.NCT06812754Written as Fezolinetant
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through MenopauseCompletedPhase 3Astellas Pharma IncNCT06206408Written as Fezolinetant
- A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through MenopauseCompletedPhase 3Astellas Pharma China, Inc.NCT04234204Written as Fezolinetant
- A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With MenopauseCompletedPhase 3Astellas Pharma China, Inc.NCT04451226Written as Fezolinetant
- Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot FlashesCompletedPhase 2Ogeda S.A.NCT05419908Written as Fezolinetant
- A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)CompletedPhase 2Astellas Pharma Global Development, Inc.NCT03192176Written as Fezolinetant
- A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through MenopauseCompletedPhase 3Astellas Pharma Global Development, Inc.NCT04003389Written as fezolinetant
- A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2CompletedPhase 3Astellas Pharma Global Development, Inc.NCT04003142Written as Fezolinetant
- A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through MenopauseCompletedPhase 3Astellas Pharma Global Development, Inc.NCT04003155Written as fezolinetant
- A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female SubjectsCompletedPhase 1Astellas Pharma China, Inc.NCT04793204Written as fezolinetant
Codes
What other systems call fezolinetant · ClinicalTrials.gg INT000489
- MeSH (NLM) C000608808fezolinetantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 83VNE45KXXFEZOLINETANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27269455fezolinetantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171845FezolinetantOne source FDA
- DrugBank DB15669One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608808 | fezolinetant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 83VNE45KXX | FEZOLINETANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27269455 | fezolinetant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171845 | Fezolinetant | One source FDA |
| DrugBank | DB15669 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.